Despite new therapies, 16-19% of patients achieve very long progression-free survival on the standard THP regimen. These "exceptional responders" often present with de novo, non-visceral disease, suggesting they are a distinct subgroup that may not require immediate escalation to newer treatments.
While oncologists often continued therapy post-induction, recent trials like PATINA and HER2CLIM-05 have formally defined and validated the "maintenance treatment" concept. This provides a new, evidence-backed framework for prolonging response after initial chemotherapy cycles are complete.
Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.
The global patient population in the pivotal DESTINY-Breast09 trial had less prior exposure to modern agents like pertuzumab and T-DM1 than is typical in Western clinics. This context is crucial when applying the trial's results to more heavily pre-treated populations.
Patients with PIK3CA mutations have shorter progression-free survival but still benefit from adding pertuzumab. This identifies the mutation as a prognostic marker for a poorer outcome, not a predictive marker of resistance to the dual HER2 blockade itself.
In addition to improving systemic progression-free survival, maintenance therapies with palbociclib (PATINA trial) and tucatinib (HER2CLIM-05 trial) both demonstrated a benefit in reducing central nervous system (CNS) progression, a critical secondary benefit for HER2+ patients.